
Fabio M Iwamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7850065/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	10.7	776
2	lmmune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 2019, 25, 462-469.	30.7	569
3	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine, 2018, 16, 142.	4.4	376
4	Patterns of care in elderly glioblastoma patients. Annals of Neurology, 2008, 64, 628-634.	5.3	177
5	Atypical and anaplastic meningiomas treated with bevacizumab. Journal of Neuro-Oncology, 2012, 109, 187-193.	2.9	155
6	Glioblastoma in the elderly. Cancer, 2009, 115, 3758-3766.	4.1	103
7	Frailty in Geriatric Glioblastoma Patients: A Predictor of Operative Morbidity and Outcome. World Neurosurgery, 2016, 89, 362-367.	1.3	98
8	Primary dural lymphomas: a review. Neurosurgical Focus, 2006, 21, 1-5.	2.3	96
9	Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer, 2012, 118, 5595-5600.	4.1	95
10	Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. Journal of Neuro-Oncology, 2012, 109, 391-397.	2.9	58
11	Prognosis and patterns of care in elderly patients with glioma. Cancer, 2009, 115, 5534-5540.	4.1	51
12	Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. Journal of Neuro-Oncology, 2008, 88, 293-298.	2.9	49
13	Age-Specific Signatures of Glioblastoma at the Genomic, Genetic, and Epigenetic Levels. PLoS ONE, 2013, 8, e62982.	2.5	49
14	Craniotomy and Survival for Primary Central Nervous System Lymphoma. Neurosurgery, 2019, 84, 935-944.	1.1	46
15	The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma. World Neurosurgery, 2015, 84, 913-919.	1.3	44
16	Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. Journal of Neuro-Oncology, 2018, 137, 303-311.	2.9	43
17	A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. Journal of Neuro-Oncology, 2008, 87, 85-90.	2.9	40
18	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2021, 2, 1372-1386.	13.2	39

Fabio M Iwamoto

#	Article	IF	CITATIONS
19	MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. PLoS ONE, 2014, 9, e114398.	2.5	38
20	The genetic landscape of dural marginal zone lymphomas. Oncotarget, 2016, 7, 43052-43061.	1.8	28
21	Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Frontiers in Oncology, 2014, 4, 90.	2.8	25
22	The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. Journal of Neuro-Oncology, 2017, 132, 189-197.	2.9	25
23	Primary Brain Tumors in the Elderly. Current Neurology and Neuroscience Reports, 2010, 10, 252-258.	4.2	23
24	An Update on Primary Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America, 2006, 20, 1267-1285.	2.2	21
25	Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection. Archives in Cancer Research, 2016, 4, .	0.3	18
26	Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma. Practical Radiation Oncology, 2016, 6, 306-314.	2.1	17
27	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
28	Immunotherapy Against Gliomas: is the Breakthrough Near?. Drugs, 2019, 79, 1839-1848.	10.9	10
29	Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma. British Journal of Neurosurgery, 2020, 34, 690-696.	0.8	10
30	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. Journal of Neurosurgery, 2020, 132, 1667-1672.	1.6	10
31	Factorial clinical trials: a new approach to phase II neuro-oncology studies. Neuro-Oncology, 2015, 17, 174-176.	1.2	6
32	Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas. Neurology, 2022, 98, .	1.1	6
33	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideâ,,¢ Assay. Clinical Breast Cancer, 2022, 22, e457-e462.	2.4	6
34	Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. Journal of Immunotherapy, 2022, 45, 254-262.	2.4	6
35	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. Lancet Oncology, The, 2017, 18, e709-e710.	10.7	5
36	ATIM-34. RATES AND OUTCOMES OF COMBINATION TUMOR TREATING FIELDS AND IMMUNOTHERAPY IN AÂGLIOMA COHORT. Neuro-Oncology, 2016, 18, vi25-vi25.	1.2	2

#	Article	IF	CITATIONS
37	Primary Central Nervous System Tumors in the Aging Population. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 182-187.	0.7	0
38	RTHP-37. RATES AND IMPACT OF COMPLIANCE WITH TUMOR TREATING FIELDS THERAPY IN AÂGLIOMA COHORT. Neuro-Oncology, 2016, 18, vi182-vi182.	1.2	0
39	ATIM-07. STUDY OF PEMBROLIZUMAB, TUMOR TREATMENT FIELDS (OPTUNE®) AND TEMOZOLOMIDE FOR OLDER SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi27-vi27.	1.2	0
40	INNV-06. FACTORS INFLUENCING RECEPTIVITY TO CLINICAL RESEARCH IN AN URBAN NEURO-ONCOLOGY PRACTICE. Neuro-Oncology, 2018, 20, vi139-vi139.	1.2	0
41	QOLP-05. THE EFFECT OF RESILIENCE ON QUALITY OF LIFE IN PATIENTS WITH HIGH GRADE GLIOMAS AND THEIR CAREGIVERS. Neuro-Oncology, 2018, 20, vi215-vi215.	1.2	0
42	CTNI-25. PHASE IB CLINICAL TRIAL OF CHRONIC CONVECTION-ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii47-ii48.	1.2	0